Mr. Lynn D. Torbeck is a Pharmtech editorial advisory board (EAB) member.
Mr. Lynn D. Torbeck
Principal Statistician
Torbeck & Associates
Lynn D. Torbeck is a consultant specializing in applied statistics and experimental design for pharmaceutical and biopharmaceutical development, quality assurance and control, validation, and production under the CGMPs. Areas of expertise include quality by design, design space, OOS, SQC/SPC, statistical PAT, assay validation, sampling plans, and setting specification criteria. Torbeck has been active in the pharmaceutical industry in statistics, quality, and management since 1975; he has been president of Torbeck and Assoc., Inc. since 1988. He has worked with a wide variety of companies, including pharmaceuticals, biotechnology, fine chemicals, medical devices, and cosmetics. Torbeck is the author of several books on validation and has published a number of journal articles.
Torbeck has been a member of the Editorial Advisory Board of Pharmaceutical Technology since 1999, and was elected to the PDA Scientific Advisory Board (SAB) in 2002 and the USP Statistics Expert Committee for a second five-year term in 2005. He was chair of the PDA’s SAB Out-Of-Specification committee. He won the PDA TRI Excellence in Teaching Award in 1997 and again in 2007. He is also a member of the ASTM E-11, statistics, and E-55, PAT, committees.
Torbeck is a member of the American Statistical Association, PDA, Senior Member of the American Society for Quality, ASQ, ASTM, and is past president of the Chicago Chapter of the American Statistical Association. He is a past Book Reviews Editor for the Journal of Quality Technology, a publication of the American Society for Quality. He holds an AAS degree in Electronics and BS and MS degrees in Statistics with minors in Operations Research and Computer Science.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.